Laurus Labs Ltd
P&L
Quarterly Consolidated
vs Q3 FY26
Laurus Labs Reports Strong FY26 Results: Revenue Up 23%, Net Profit Up 148%
30 Apr 2026 · 30 Apr, 3:31 pm
Summary
Laurus Labs delivered a strong financial performance for both Q4 and the full fiscal year FY26. For the full year, revenues grew by 23% to ₹6,813 Cr, while EBITDA soared by 64% to ₹1,826 Cr, with margins expanding to 26.8%. Net Profit also saw a substantial increase of 148% to ₹889 Cr. Management highlighted accelerated performance driven by successful NCE programs, new launches, and sustained leadership in the Anti-retroviral segment, alongside strategic investments in novel technologies for future growth. The company remains confident in its outlook, supported by a resilient business model and robust demand across its integrated offerings.
Key Highlights
- 1
Laurus Labs reported robust full-year FY26 revenues of ₹6,813 Cr, marking a significant 23% year-over-year growth.
- 2
Full-year FY26 EBITDA reached ₹1,826 Cr, representing a strong 64% increase year-over-year, with EBITDA margins expanding by 6.7 percentage points to 26.8%.
- 3
Net Profit for FY26 surged by 148% to ₹889 Cr, demonstrating substantial profitability improvement.
- 4
For Q4 FY26, revenues stood at ₹1,812 Cr, achieving a 5% year-over-year growth, while EBITDA grew 10% to ₹523 Cr with margins at 28.9%.
- 5
The CDMO business division was a key growth driver, with its revenues climbing 36% to ₹2,080 Cr for the full year FY26.
- 6
Gross margins improved significantly by over 5.0 percentage points to 60.4% in FY26, primarily due to a favorable CDMO product mix.
- 7
The company declared a second interim dividend of ₹1.2 per share during Q4 FY26.
Management Comments
Dr. Satyanarayana Chava
We significantly accelerated our performance in FY 26, delivering strong revenue growth and expanded profitability, backed by successful commercial supplies for NCE programs, new launches ramp-up and sustained leadership in Anti-retroviral segment. The transformation of our portfolio is well underway, and momentum is building. We are making significant investments in novel technologies, scale and strengthening integrated capabilities offerings towards laying foundation for future growth. In the face of macro-economic volatility, our business model has proven resilient and we remain well positioned to execute on our growth strategy with continued progress on our EHS/ESG initiatives.
V V Ravi Kumar
We sustained strong operating performance for the current quarter Q4 FY 26. We have achieved revenues of ₹ 1,812 Cr, representing 5% growth and EBITDA of ₹ 523 Cr, representing 10% growth over the previous year Q4 FY 25. The EBITDA margins were strong at 28.9%, supported by continuing operating leverage. Overall, we reported strong FY 26 performance, reflecting continued robust demand for integrated offering across CDMO and Affordable Medicines business. We achieved ₹ 6,813 Cr in revenues, representing 23% growth and EBITDA of ₹ 1,826 Cr, representing 64% growth, resulting in 26.8% EBITDA margins marking significant >6% pts improvement over the previous year. Gross margins improved by over 5% pts to 60.4% due to favorable CDMO mix. These results demonstrate the strength of our business and give us confidence in our outlook. Our Balance sheet remain well positioned to support key CAPEX program ahead with continued focus on operational excellence.
Informational and educational content only. Not investment advice.